CoChat

Interleukin-1β Attenuates Myofibroblast Formation and Extracellular Matrix Production in Dermal and Lung Fibroblasts Exposed to Transforming Growth Factor-β1

Open access

The DOI matches its Crossref record; 75 of the 76 references it cites were found in a registry or an index.

Abstract

One of the most potent pro-fibrotic cytokines is transforming growth factor (TGFβ). TGFβ is involved in the activation of fibroblasts into myofibroblasts, resulting in the hallmark of fibrosis: the pathological accumulation of collagen. Interleukin-1β (IL1β) can influence the severity of fibrosis, however much less is known about the direct effects on fibroblasts. Using lung and dermal fibroblasts, we have investigated the effects of IL1β, TGFβ1, and IL1β in combination with TGFβ1 on myofibroblast formation, collagen synthesis and collagen modification (including prolyl hydroxylase, lysyl hydroxylase and lysyl oxidase), and matrix metalloproteinases (MMPs). We found that IL1β alone has no obvious pro-fibrotic effect on fibroblasts. However, IL1β is able to inhibit the TGFβ1-induced myofibroblast formation as well as collagen synthesis. Glioma-associated oncogene homolog 1 (GLI1), the Hedgehog transcription factor that is involved in the transformation of fibroblasts into myofibroblasts is upregulated by TGFβ1. The addition of IL1β reduced the expression of GLI1 and thereby also indirectly inhibits myofibroblast formation. Other potentially anti-fibrotic effects of IL1β that were observed are the increased levels of MMP1, -2, -9 and -14 produced by fibroblasts exposed to TGFβ1/IL1β in comparison with fibroblasts exposed to TGFβ1 alone. In addition, IL1β decreased the TGFβ1-induced upregulation of lysyl oxidase, an enzyme involved in collagen cross-linking. Furthermore, we found that lung and dermal fibroblasts do not always behave identically towards IL1β. Suppression of COL1A1 by IL1β in the presence of TGFβ1 is more pronounced in lung fibroblasts compared to dermal fibroblasts, whereas a higher upregulation of MMP1 is seen in dermal fibroblasts. The role of IL1β in fibrosis should be reconsidered, and the differences in phenotypical properties of fibroblasts derived from different organs should be taken into account in future anti-fibrotic treatment regimes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0091559

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Effects of IL1β on TGFβ1-induced αSMA synthesis in dermal and lung fibroblasts. HDFa and HLFa were treated with IL1β, TGFβ1, or a combination of both, for 24 and 48 h. (A–B) The mRNA levels of ACTA2 of HDFa and HLFa were measured with qRT-PCR and expressed as fold change compared to untreated control. (C) Representative immunofluorescence stainings for αSMA are shown for HDFa (upper panel) and HLFa (lower panel). White scale bar represents 100 μm. (D) Representative TissueFAXS plots showing the % of positive cells (upper right corner) for αSMA positive fibroblasts in HDFa. (E–F) Quantification of the % of cells positive for αSMA are shown for HDFa and HLFa respectively.
Figure 1 Effects of IL1β on TGFβ1-induced αSMA synthesis in dermal and lung fibroblasts. HDFa and HLFa were treated with IL1β, TGFβ1, or a combination of both, for 24 and 48 h. (A–B) The mRNA levels of ACTA2 of HDFa and HLFa were measured with qRT-PCR and expressed as fold change compared to untreated control. (C) Representative immunofluorescence stainings for αSMA are shown for HDFa (upper panel) and HLFa (lower panel). White scale bar represents 100 μm. (D) Representative TissueFAXS plots showing the % of positive cells (upper right corner) for αSMA positive fibroblasts in HDFa. (E–F) Quantification of the % of cells positive for αSMA are shown for HDFa and HLFa respectively.CC BY · PubMed Central
Figure 2 Post-treatment effects of IL1β on TGFβ1-induced αSMA synthesis in dermal and lung fibroblasts. Fibroblasts were pre-treated with TGFβ1 for 48 h followed by IL1β for 48 h. (A–B) The mRNA levels of ACTA2 of HDFa and HLFa were measured with qRT-PCR and expressed as fold change compared to untreated control. (C) Representative immunofluorescence stainings for αSMA are shown for HDFa (upper panel) and HLFa (lower panel). White scale bar represents 100 μm. (D) Representative TissueFAXS plots showing the % of positive cells (upper right corner) for αSMA positive fibroblasts in HDFa. (E–F) Quantification of the % of cells positive for αSMA are shown for HDFa and HLFa respectively.
Figure 2 Post-treatment effects of IL1β on TGFβ1-induced αSMA synthesis in dermal and lung fibroblasts. Fibroblasts were pre-treated with TGFβ1 for 48 h followed by IL1β for 48 h. (A–B) The mRNA levels of ACTA2 of HDFa and HLFa were measured with qRT-PCR and expressed as fold change compared to untreated control. (C) Representative immunofluorescence stainings for αSMA are shown for HDFa (upper panel) and HLFa (lower panel). White scale bar represents 100 μm. (D) Representative TissueFAXS plots showing the % of positive cells (upper right corner) for αSMA positive fibroblasts in HDFa. (E–F) Quantification of the % of cells positive for αSMA are shown for HDFa and HLFa respectively.CC BY · PubMed Central
Figure 3 Effects of IL1β on TGFβ1-induced SM22α synthesis in dermal and lung fibroblasts. HDFa and HLFa were treated with IL1β, TGFβ1, or a combination of both, for 24 and 48 h. (A–B) The mRNA levels of TAGLN of HDFa and HLFa were measured with qRT-PCR and expressed as fold change compared to untreated control. (C) Representative immunofluorescence stainings for SM22α are shown for HDFa (upper panel) and HLFa (lower panel). White scale bar represents 100 μm. (D) Representative TissueFAXS plots showing the % of positive cells (upper right corner) for SM22α positive fibroblasts in HDFa. (E–F) Quantification of the % of cells positive for SM22α are shown for HDFa and HLFa respectively.
Figure 3 Effects of IL1β on TGFβ1-induced SM22α synthesis in dermal and lung fibroblasts. HDFa and HLFa were treated with IL1β, TGFβ1, or a combination of both, for 24 and 48 h. (A–B) The mRNA levels of TAGLN of HDFa and HLFa were measured with qRT-PCR and expressed as fold change compared to untreated control. (C) Representative immunofluorescence stainings for SM22α are shown for HDFa (upper panel) and HLFa (lower panel). White scale bar represents 100 μm. (D) Representative TissueFAXS plots showing the % of positive cells (upper right corner) for SM22α positive fibroblasts in HDFa. (E–F) Quantification of the % of cells positive for SM22α are shown for HDFa and HLFa respectively.CC BY · PubMed Central
Figure 4 Post-treatment effects of IL1β on TGFβ1-induced SM22α synthesis in dermal and lung fibroblasts. Fibroblasts were pre-treated with TGFβ1 for 48 h followed by IL1β for 48 h. (A–B) The mRNA levels of TAGLN of HDFa and HLFa were measured with qRT-PCR and expressed as fold change compared to untreated control. (C) Representative immunofluorescence stainings for SM22α are shown for HDFa (upper panel) and HLFa (lower panel). White scale bar represents 100 μm. (D) Representative TissueFAXS plots showing the % of positive cells (upper right corner) for SM22α positive fibroblasts in HDFa. (E–F) Quantification of the % of cells positive for SM22α are shown for HDFa and HLFa respectively.
Figure 4 Post-treatment effects of IL1β on TGFβ1-induced SM22α synthesis in dermal and lung fibroblasts. Fibroblasts were pre-treated with TGFβ1 for 48 h followed by IL1β for 48 h. (A–B) The mRNA levels of TAGLN of HDFa and HLFa were measured with qRT-PCR and expressed as fold change compared to untreated control. (C) Representative immunofluorescence stainings for SM22α are shown for HDFa (upper panel) and HLFa (lower panel). White scale bar represents 100 μm. (D) Representative TissueFAXS plots showing the % of positive cells (upper right corner) for SM22α positive fibroblasts in HDFa. (E–F) Quantification of the % of cells positive for SM22α are shown for HDFa and HLFa respectively.CC BY · PubMed Central
Figure 5 Effects of IL1β on TGFβ1-induced gene expression of Hedgehog pathway effector GLI1 and its isoform GLI1ΔN in dermal and lung fibroblasts. (A–B) HDFa and HLFa were treated with IL1β, TGFβ, or a combination of both for 24 and 48 h. The mRNA levels of GLI1 were measured with qRT-PCR and expressed as fold change compared to untreated control. (C–D) The mRNA level of GLI1 in HDFa and HLFa. Fibroblasts were pre-treated with TGFβ1 for 48 h followed by IL1β for 48 h and quantified by qRT-PCR and expressed as fold change compared to untreated control. (E–F) HDFa and HLFa were treated with IL1β, TGFβ1, or a combination of both, for 24 and 48 h. The mRNA levels of GLI1ΔN were measured with qRT-PCR and expressed as fold change compared to untreated control. (G–H) The mRNA level of GLI1ΔN in HDFa and HLFa. Fibroblasts were pre-treated with TGFβ1 for 48 h followed by IL1β for 48 h and quantified by qRT-PCR and expressed as fold change compared to untreated control.
Figure 5 Effects of IL1β on TGFβ1-induced gene expression of Hedgehog pathway effector GLI1 and its isoform GLI1ΔN in dermal and lung fibroblasts. (A–B) HDFa and HLFa were treated with IL1β, TGFβ, or a combination of both for 24 and 48 h. The mRNA levels of GLI1 were measured with qRT-PCR and expressed as fold change compared to untreated control. (C–D) The mRNA level of GLI1 in HDFa and HLFa. Fibroblasts were pre-treated with TGFβ1 for 48 h followed by IL1β for 48 h and quantified by qRT-PCR and expressed as fold change compared to untreated control. (E–F) HDFa and HLFa were treated with IL1β, TGFβ1, or a combination of both, for 24 and 48 h. The mRNA levels of GLI1ΔN were measured with qRT-PCR and expressed as fold change compared to untreated control. (G–H) The mRNA level of GLI1ΔN in HDFa and HLFa. Fibroblasts were pre-treated with TGFβ1 for 48 h followed by IL1β for 48 h and quantified by qRT-PCR and expressed as fold change compared to untreated control.CC BY · PubMed Central
Figure 6 Effects of IL1β on TGFβ1-induced collagen type I synthesis in dermal and lung fibroblasts. (A–B) HDFa and HLFa were treated with IL1β, TGFβ1, or a combination of both, for 24 and 48 h. The mRNA levels of COL1A1 were measured with qRT-PCR and expressed as fold change compared to untreated control. (C) Visualisation of synthesized collagen (intracellular) by HDFa (upper panel) and HLFa (lower panel) treated for 7 days with IL1β, TGFβ1 and in combination thereof. White scale bar of each image represents 100 μm. (D) Representative TissueFAXS plots showing the % of positive cells (upper right corner) for intracellular collagen type I in HDFa. (E–F) Quantification of the % of cells positive for intracellular collagen type I are shown for HDFa and HLFa respectively.
Figure 6 Effects of IL1β on TGFβ1-induced collagen type I synthesis in dermal and lung fibroblasts. (A–B) HDFa and HLFa were treated with IL1β, TGFβ1, or a combination of both, for 24 and 48 h. The mRNA levels of COL1A1 were measured with qRT-PCR and expressed as fold change compared to untreated control. (C) Visualisation of synthesized collagen (intracellular) by HDFa (upper panel) and HLFa (lower panel) treated for 7 days with IL1β, TGFβ1 and in combination thereof. White scale bar of each image represents 100 μm. (D) Representative TissueFAXS plots showing the % of positive cells (upper right corner) for intracellular collagen type I in HDFa. (E–F) Quantification of the % of cells positive for intracellular collagen type I are shown for HDFa and HLFa respectively.CC BY · PubMed Central
Figure 7 Effects of IL1β on TGFβ1-induced production of extracellular collagen type I in dermal and lung fibroblasts. (A) Visualisation of deposited extracellular collagen by HDFa (upper panel) and HLFa (lower panel) treated for 7 days with IL1β, TGFβ1 and in combination thereof. White scale bar of each image represents 100 μm. (B) Representative TissueFAXS plots showing the % of positive cells (upper right corner) for extracellular collagen type I in HDFa. (C–D) Quantification of the % of cells surrounded by extracellular collagen type I protein are shown for HDFa and HLFa respectively. (E–F) Fibroblasts were pre-treated with TGFβ1 for 48 h followed by IL1β for 48 h. The mRNA levels of COL1A1 of HDFa and HLFa were measured with qRT-PCR and expressed as fold change compared to untreated control.
Figure 7 Effects of IL1β on TGFβ1-induced production of extracellular collagen type I in dermal and lung fibroblasts. (A) Visualisation of deposited extracellular collagen by HDFa (upper panel) and HLFa (lower panel) treated for 7 days with IL1β, TGFβ1 and in combination thereof. White scale bar of each image represents 100 μm. (B) Representative TissueFAXS plots showing the % of positive cells (upper right corner) for extracellular collagen type I in HDFa. (C–D) Quantification of the % of cells surrounded by extracellular collagen type I protein are shown for HDFa and HLFa respectively. (E–F) Fibroblasts were pre-treated with TGFβ1 for 48 h followed by IL1β for 48 h. The mRNA levels of COL1A1 of HDFa and HLFa were measured with qRT-PCR and expressed as fold change compared to untreated control.CC BY · PubMed Central
Figure 8 Effects of IL1β and TGFβ1 on the expression of collagen type III in dermal and lung fibroblasts. (A–B) HDFa and HLFa were treated with IL1β, TGFβ1, or a combination of both, for 24 and 48 h. The mRNA levels of COL3A1 were measured with qRT-PCR and expressed as fold change compared to untreated control. (C–D) The mRNA level of COL3A1 in HDFa and HLFa. Fibroblasts were pre-treated with TGFβ1 for 48 h followed by IL1β for 48 h and quantified by qRT-PCR and expressed as fold change compared to untreated control.
Figure 8 Effects of IL1β and TGFβ1 on the expression of collagen type III in dermal and lung fibroblasts. (A–B) HDFa and HLFa were treated with IL1β, TGFβ1, or a combination of both, for 24 and 48 h. The mRNA levels of COL3A1 were measured with qRT-PCR and expressed as fold change compared to untreated control. (C–D) The mRNA level of COL3A1 in HDFa and HLFa. Fibroblasts were pre-treated with TGFβ1 for 48 h followed by IL1β for 48 h and quantified by qRT-PCR and expressed as fold change compared to untreated control.CC BY · PubMed Central
Figure 9 Effects of IL1β and TGFβ1 on the expression of the intracellular collagen-modifying enzymes prolyl hydroxylase (P4HA1, P4HB) and lysyl hydroxylase (PLOD1, PLOD2) in dermal and lung fibroblasts. (A–H) HDFa and HLFa were treated with IL1β, TGFβ1, or a combination of both, for 24 and 48 h. The mRNA levels of P4HA1, P4HB, PLOD1 and PLOD2 were measured with qRT-PCR and expressed as fold change compared to untreated control. (I–J) The mRNA levels of PLOD2 in HDFa and HLFa. Fibroblasts were pre-treated with TGFβ1 for 48 h followed by IL1β for 48 h and quantified by qRT-PCR and expressed as fold change compared to untreated control.
Figure 9 Effects of IL1β and TGFβ1 on the expression of the intracellular collagen-modifying enzymes prolyl hydroxylase (P4HA1, P4HB) and lysyl hydroxylase (PLOD1, PLOD2) in dermal and lung fibroblasts. (A–H) HDFa and HLFa were treated with IL1β, TGFβ1, or a combination of both, for 24 and 48 h. The mRNA levels of P4HA1, P4HB, PLOD1 and PLOD2 were measured with qRT-PCR and expressed as fold change compared to untreated control. (I–J) The mRNA levels of PLOD2 in HDFa and HLFa. Fibroblasts were pre-treated with TGFβ1 for 48 h followed by IL1β for 48 h and quantified by qRT-PCR and expressed as fold change compared to untreated control.CC BY · PubMed Central
Figure 10 Effects of IL1β and TGFβ1 on the expression and activity level of lysyl oxidase in dermal and lung fibroblasts. (A–B) HDFa and HLFa were treated with IL1β, TGFβ1, or a combination of both, for 24 and 48 h. The mRNA levels of LOX were measured with qRT-PCR and expressed as fold change compared to untreated control. (C–D) Quantification of lysyl oxidase activity as secreted in the culture medium by HDFa and HLFa treated with IL1β, TGFβ1, or a combination of both for 24 and 48 h.
Figure 10 Effects of IL1β and TGFβ1 on the expression and activity level of lysyl oxidase in dermal and lung fibroblasts. (A–B) HDFa and HLFa were treated with IL1β, TGFβ1, or a combination of both, for 24 and 48 h. The mRNA levels of LOX were measured with qRT-PCR and expressed as fold change compared to untreated control. (C–D) Quantification of lysyl oxidase activity as secreted in the culture medium by HDFa and HLFa treated with IL1β, TGFβ1, or a combination of both for 24 and 48 h.CC BY · PubMed Central
Figure 11 Effects of IL1β and TGFβ1 on the expression level of matrix metalloproteinases in dermal and lung fibroblasts. HDFa and HLFa were treated with IL1β, TGFβ1, or a combination of both, for 24 and 48 h. (A–H) The mRNA levels of MMP1, −2, −9 and 14 were measured with qRT-PCR and expressed as fold change compared to untreated control.
Figure 11 Effects of IL1β and TGFβ1 on the expression level of matrix metalloproteinases in dermal and lung fibroblasts. HDFa and HLFa were treated with IL1β, TGFβ1, or a combination of both, for 24 and 48 h. (A–H) The mRNA levels of MMP1, −2, −9 and 14 were measured with qRT-PCR and expressed as fold change compared to untreated control.CC BY · PubMed Central
Figure 12 Post-treatment effects of IL1β on TGFβ1-stimulated dermal and lung fibroblasts on the expression level of matrix metalloproteinases. Fibroblasts were pre-treated with TGFβ1 for 48 h followed by IL1β for 48 h and quantified by qRT-PCR and expressed as fold change compared to untreated control. (A–B) The mRNA levels of MMP1 in HDFa and HLFa. (C–D) The mRNA levels of MMP9 in HDFa and HLFa.
Figure 12 Post-treatment effects of IL1β on TGFβ1-stimulated dermal and lung fibroblasts on the expression level of matrix metalloproteinases. Fibroblasts were pre-treated with TGFβ1 for 48 h followed by IL1β for 48 h and quantified by qRT-PCR and expressed as fold change compared to untreated control. (A–B) The mRNA levels of MMP1 in HDFa and HLFa. (C–D) The mRNA levels of MMP9 in HDFa and HLFa.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 75 references

Cited by

See all 118

Metadata

Authors
Mia, M. M., Boersema, M., & Bank, R. A.
Affiliations
University Medical Center Groningen (NL)
Corresponding author
Bank, Ruud A.
Venue
PLoS ONE
Published
2014-03-12
Volume
9
Issue
3
Pages
e91559
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2155540606
Cited by
109
References
76
Citations by year
2026: 6 · 2025: 8 · 2024: 14 · 2023: 5 · 2022: 6 · 2021: 6 · 2020: 11 · 2019: 13 · 2018: 11 · 2017: 9 · 2016: 5 · 2015: 13 · 2014: 2
FWCI
3.97
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
  • National University of Singapore (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
Funders
  • ZonMw (40-00506-98-9021)
  • Universitair Medisch Centrum Groningen (40-00506-98-9021)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
IL-1β, TGF-β1, myofibroblast differentiation, fibroblast activation, fibrosis, extracellular matrix synthesis, collagen synthesis, Gli1, Hedgehog signaling, matrix metalloproteinases, lysyl oxidase, collagen cross-linking, dermal fibroblasts, lung fibroblasts, COL1A1
MeSH terms
Zinc Finger Protein GLI1, Cell Differentiation, Dose-Response Relationship, Drug, Drug Interactions, Extracellular Matrix, Fibroblasts, Humans, Lung, Skin, Signal Transduction, Oncogene Proteins, Trans-Activators, Gene Expression Regulation, Enzymologic, Matrix Metalloproteinases, Collagen Type I, Collagen Type III, Interleukin-1beta, Transforming Growth Factor beta1, Hedgehog Proteins, Myofibroblasts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interleukin-1β Attenuates Myofibroblast Formation and Extracellular Matrix Production in Dermal and Lung Fibroblasts Exposed to Transforming Growth Factor-β1. https://app.cochat.ai/papers/10.1371/journal.pone.0091559
The paper
Mia, M. M., Boersema, M., & Bank, R. A. (2014). Interleukin-1β Attenuates Myofibroblast Formation and Extracellular Matrix Production in Dermal and Lung Fibroblasts Exposed to Transforming Growth Factor-β1. PLoS ONE. https://doi.org/10.1371/journal.pone.0091559

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.